Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Oestrogen Receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01776008
What this trial is testing

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeRecurrent Breast Carcinoma+5 more
National Cancer Institute (NCI) 16
Very early researchEnded earlyNCT00651976
What this trial is testing

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 213
Not applicableEnded earlyNCT05560685
What this trial is testing

SMART-ER: Symptom Monitoring With Patient-reported Outcomes

Who this might be right for
Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 10
Testing effectiveness (Phase 2)Study completedNCT00871858
What this trial is testing

Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

Who this might be right for
Breast Cancer
Institut Bergonié 120
Not applicableActive Not RecruitingNCT04597580
What this trial is testing

Personalised Disease Monitoring in Metastatic Breast Cancer

Who this might be right for
Breast Cancer MetastaticEstrogen Receptor-positive Breast Cancer
The Christie NHS Foundation Trust 97
Testing effectiveness (Phase 2)Study completedNCT01160718
What this trial is testing

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
Swiss Cancer Institute 46
Not applicableUnknownNCT03768479
What this trial is testing

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerFulvestrant
First Affiliated Hospital Xi'an Jiaotong University 68
Testing effectiveness (Phase 2)Study completedNCT00365599
What this trial is testing

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Who this might be right for
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Early research (Phase 1)Ended earlyNCT03128619
What this trial is testing

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeInvasive Breast Carcinoma+14 more
Jonsson Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Large-scale testing (Phase 3)Looking for participantsNCT07647328
What this trial is testing

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 150
Testing effectiveness (Phase 2)WithdrawnNCT01953445
What this trial is testing

Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine
Not applicableStudy completedNCT03523195
What this trial is testing

Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+16 more
Fred Hutchinson Cancer Center 20
Not applicableStudy completedNCT03719495
What this trial is testing

Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast CancerHealthy
Duke University 68
Testing effectiveness (Phase 2)WithdrawnNCT03377101
What this trial is testing

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI)
Not applicableStudy completedNCT01899079
What this trial is testing

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 217
Testing effectiveness (Phase 2)Active Not RecruitingNCT04567420
What this trial is testing

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Who this might be right for
Breast Cancer
Criterium, Inc. 70
Early research (Phase 1)Study completedNCT02248090
What this trial is testing

AZD9496 First Time in Patients Ascending Dose Study

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 45
Testing effectiveness (Phase 2)Study completedNCT02871791
What this trial is testing

Palbociclib With Everolimus + Exemestane In BC

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
Dana-Farber Cancer Institute 41
Next Page